Medable has introduced its Agentic Accelerator Program aimed at enhancing clinical development through agentic AI technology.
The new program is designed to assist life sciences companies, including sponsors and contract research organizations (CROs), in effectively integrating agentic AI into their clinical processes. It offers comprehensive support that encompasses onboarding, governance, and change management, ensuring that organizations can derive value from AI from the outset. Notably, despite the rapid evolution of AI capabilities, only a small percentage of life sciences leaders have successfully scaled AI across their enterprises, highlighting a significant gap in the industry.
Medable’s initiative promises to expedite the time to value by providing strategic direction and a streamlined implementation pathway. The program is backed by a dedicated team of experts and engineers who facilitate the quick adoption of standard agentic applications while also allowing for the development of tailored workflows. This approach aims to enhance productivity and reduce costs associated with clinical trials, as emphasized by Medable's CEO, Michelle Longmire.
Furthermore, the Agentic Accelerator Program is now available to all users of Medable's Agent Studio, a platform that supports the deployment of AI agents throughout the clinical development lifecycle. By combining features such as no-code agent creation and robust compliance controls, Medable seeks to automate operational tasks while ensuring regulatory adherence and transparency. This development represents a significant step towards transforming clinical trials, making them more efficient and scalable.
The introduction of this program signals a pivotal moment in the life sciences sector as companies increasingly look to leverage AI for improved clinical outcomes. As the landscape evolves, partnerships with technology providers like Medable could become essential for organizations aiming to stay competitive and enhance their clinical development strategies.